1887

Chapter 10 : Emerging Considerations in Virus-Based Gene Transfer Systems

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Emerging Considerations in Virus-Based Gene Transfer Systems, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch10-1.gif /docserver/preview/fulltext/10.1128/9781555819637/9781555816209.ch10-2.gif

Abstract:

Accompanying the development of molecular biological tools for identifying gene sequences and functions has been the development of novel gene transfer vectors for shuttling gene sequences between different organisms. As illustrated in Fig. 1, a search of the PubMed database reveals a large number of publications describing the application of frequently used recombinant viruses. The use of these vector systems has continued to increase significantly since the publication of the 4th edition of this book in 2006. This increase has been driven by several factors, including the proliferation of gene therapy protocols (Fig. 2), the increased recognition of the general utility of viral vectors as gene transfer agents for elucidating and studying gene function, and the increased commercial access of the reagents required to produce these viral vectors. Additionally, our understanding of the molecular biology of a wide variety of virus families has increased to the point where novel chimeric viruses, containing the unique properties of two or more viruses, are being constructed routinely. Due to their unique nature, these viruses pose special challenges in risk assessment.

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Number of PubMed citations found for recombinant viral vectors.

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Number of human gene therapy clinical protocols approved worldwide by year as of July 2015. Source data are from reference .

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Summary of gene transfer clinical trial delivery methods worldwide through July 2015. Source data are from reference .

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555819637.ch10
1. van Oers MM. 2011. Opportunities and challenges for the baculovirus expression system. J Invertebr Pathol 107(Suppl):S3S15.[PubMed]
2. Vanderplasschen A, Pastoret PP. 2003. The uses of poxviruses as vectors. Curr Gene Ther 3:583595.[PubMed]
3. Lundstrom K,. 2003. Virus-based vectors for gene expression in mammalian cells: Semliki Forest Virus, p 207230. In Makrides SC (ed), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V, Amsterdam, The Netherlands.
4. Shen Y, Post L,. 2007. Viral vectors and their applications, p 539564. In Knipe DM, Howley PM (ed), Fields Virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
5. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:5972.[PubMed]
6. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9:19091917.[PubMed]
7. Rigg RJ, Chen J, Dando JS, Forestell SP, Plavec I, Böhnlein E. 1996. A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 218:290295.[PubMed]
8. Miller AD, Trauber DR, Buttimore C. 1986. Factors involved in production of helper virus-free retrovirus vectors. Somat Cell Mol Genet 12:175183.[PubMed]
9. Merten OW. 2004. State-of-the-art of the production of retroviral vectors. J Gene Med 6(Suppl 1):S105S124.[PubMed]
10. Scadden DT, Fuller B, Cunningham JM. 1990. Human cells infected with retrovirus vectors acquire an endogenous murine provirus. J Virol 64:424427.[PubMed]
11. Ronfort C, Girod A, Cosset FL, Legras C, Nigon VM, Chebloune Y, Verdier G. 1995. Defective retroviral endogenous RNA is efficiently transmitted by infectious particles produced on an avian retroviral vector packaging cell line. Virology 207:271275.[PubMed]
12. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J Virol 72:84638471.[PubMed]
13. Wickersham IR, Lyon DC, Barnard RJO, Mori T, Finke S, Conzelmann K-K, Young JAT, Callaway EM. 2007. Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53:639647.[PubMed]
14. Braun A. 2006. Biosafety in handling gene transfer vectors. Curr Protoc Hum Genet 50:12.1.112.1.18.
15. Kamimura K, Suda T, Zhang G, Liu D. 2011. Advances in gene delivery systems. Pharmaceut Med 25:293306.[PubMed]
16. Warnock JN, Daigre C, Al-Rubeai M. 2011. Introduction to viral vectors. Methods Mol Biol 737:125.[PubMed]
17. Alcami A, Moss B,. 2010. Smallpox vaccines, p 115. In Khan AS, Smith GL (ed), Scientific Review of Variola Research, 1999–2010. Khan, AS. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10665/70508/1/WHO_HSE_GAR_BDP_2010.3_eng.pdf.
18. Damon IK,. 2013. Poxviruses, p 21602184. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
19. Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG, Pearson ML, Anderson LJ Advisory Committee on Immunization Practices, Healthcare Infection Control Practices Advisory Committee. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 52(RR-7):116.[PubMed]
20. Lofquist JM, Weimert NA, Hayney MS. 2003. Smallpox: a review of clinical disease and vaccination. Am J Health Syst Pharm 60:749756, quiz 757–758.[PubMed]
21. Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Török TJ, Chapman LE, Swerdlow DL, Morgan J, Heffelfinger JD, Vitek C, Reef SE, Hasbrouck LM, Damon I, Neff L, Vellozzi C, McCauley M, Strikas RA, Mootrey G. 2005. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294:27342743.[PubMed]
22. Moss B,. 2013. Poxviridiae, p 21292159. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
23. Mackett M, Smith GL, Moss B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79:74157419.[PubMed]
24. Panicali D, Paoletti E. 1982. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79:4927493.[PubMed]
25. Moss B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93:1134111348.[PubMed]
26. Paoletti E. 1996. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 93:1134911353.[PubMed]
27. Guo ZS, Bartlett DL. 2004. Vaccinia as a vector for gene delivery. Expert Opin Biol Ther 4:901917.[PubMed]
28. Wyatt LS, Earl PL, Moss B. 2015. Generation of recombinant vaccinia viruses. Curr Protoc Microbiol 39:118.[PubMed]
29. Issacs SN (ed). 2004. Vaccinia Virus and Poxvirology: Methods and Protocols. Methods Mol Biol vol 269. Humana Press, Totowa, NJ.
30. Walsh SR, Dolin R. 2011. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert Rev Vaccines 10:12211240.[PubMed]
31. Thorne SH. 2012. Next-generation oncolytic vaccinia vectors. Methods Mol Biol 797:205215.[PubMed]
32. Sánchez-Sampedro L, Perdiguero B, Mejías-Pérez E, García-Arriaza J, Di Pilato M, Esteban M. 2015. The evolution of poxvirus vaccines. Viruses 7:17261803.[PubMed]
33. Bleckwenn NA, Golding H, Bentley WE, Shiloach J. 2005. Production of recombinant proteins by vaccinia virus in a microcarrier based mammalian cell perfusion bioreactor. Biotechnol Bioeng 90:663674.[PubMed]
34. Hebben M, Brants J, Birck C, Samama JP, Wasylyk B, Spehner D, Pradeau K, Domi A, Moss B, Schultz P, Drillien R. 2007. High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara. Protein Expr Purif 56:269278.[PubMed]
35. Jester BC, Drillien R, Ruff M, Florentz C. 2011. Using Vaccinia's innate ability to introduce DNA into mammalian cells for production of recombinant proteins. J Biotechnol 156:211213.[PubMed]
36. Guo W, Cleveland B, Davenport TM, Lee KK, Hu SL. 2013. Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity. Protein Expr Purif 90:3439.[PubMed]
37. de Oliveira TM, Rehfeld IS, Coelho Guedes MI, Ferreira JM, Kroon EG, Lobato ZI. 2011. Susceptibility of vaccinia virus to chemical disinfection. Am J Trop Hyg 85:152157.
38. Evans ME, Lesnaw JA. 2002. Infection control for gene therapy: a busy physician's primer. Clin Infect Dis 35:597605.[PubMed]
39. Evans ME,. 2003. Gene therapy and infection control, p 262278. In Wenzel RP (ed), Prevention and Control of Nosocomial Infections, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
40. Sepkowitz KA. 2003. How contagious is vaccinia? N Engl J Med 348:439446.[PubMed]
41. Jones L, Ristow S, Yilma T, Moss B. 1986. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 319:543.[PubMed]
42. Openshaw PJ, Alwan WH, Cherrie AH, Record FM. 1991. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338:459.[PubMed]
43. Rupprecht CE, Blass L, Smith K, Orciari LA, Niezgoda M, Whitfield SG, Gibbons RV, Guerra M, Hanlon CA. 2001. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N Engl J Med 345:582586.[PubMed]
44. Loeb M, Zando I, Orvidas MC, Bialachowski A, Groves D, Mahoney J. 2003. Laboratory-acquired vaccinia infection. Can Commun Dis Rep 29:134136.[PubMed]
45. Mempel M, Isa G, Klugbauer N, Meyer H, Wildi G, Ring J, Hofmann F, Hofmann H. 2003. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J Invest Dermatol 120:356358.[PubMed]
46. Moussatché N, Tuyama M, Kato SE, Castro AP, Njaine B, Peralta RH, Peralta JM, Damaso CR, Barroso PF. 2003. Accidental infection of laboratory worker with vaccinia virus. Emerg Infect Dis 9:724726.[PubMed]
47. Lewis FM, Chernak E, Goldman E, Li Y, Karem K, Damon IK, Henkel R, Newbern EC, Ross P, Johnson CC. 2006. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg Infect Dis 12:134137.[PubMed]
48. Centers for Disease Control and Prevention (CDC). 2009. Laboratory-acquired vaccinia virus infection—Virginia, 2008. MMWR Morb Mortal Wkly Rep 58:797800.[PubMed]
49. Centers for Disease Control and Prevention (CDC). 2009. Human vaccinia infection after contact with a raccoon rabies vaccine bait—Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 58:12041207.[PubMed]
50. Isaacs SN. 2004. Working safely with vaccinia virus: laboratory technique and the role of vaccinia vaccination. Methods Mol Biol 269:114.[PubMed]
51. Byers KB. 2005. Biosafety tips. See subhead, Biosafety issues in laboratory experiments using vaccinia virus vectors. Appl Biosaf 10:118122.
52. Benzekri N, Goldman E, Lewis F, Johnson CC, Reynolds SM, Reynolds MG, Damon IK. 2010. Laboratory worker knowledge, attitudes and practices towards smallpox vaccine. Occup Med (Lond) 60:7577.[PubMed]
53. MacNeil A, Reynolds MG, Damon IK. 2009. Risks associated with vaccinia virus in the laboratory. Virology 385:14.[PubMed]
54. Rotz LD, Dotson DA, Damon IK, Becher JA Advisory Committee on Immunization Practices. 2001. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 50(RR-10):125, quiz CE1–CE7.[PubMed]
55. Petersen BW, Harms TJ, Reynolds MG, Harrison LH Centers for Disease Control and Prevention. 2016. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses—recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015. MMWR Morb Mortal Wkly Rep 65:257262.[PubMed]
56. Baggs J, Chen RT, Damon IK, Rotz L, Allen C, Fullerton KE, Casey C, Nordenberg D, Mootrey G. 2005. Safety profile of smallpox vaccine: insights from the laboratory worker smallpox vaccination program. Clin Infect Dis 40:11331140.[PubMed]
57. National Institutes of Health. 2013. NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) 78 FR 66751 (November 6, 2013). The current version of the NIH Guidelines can be accessed at http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines.
58. Maetzig T, Galla M, Baum C, Schambach A. 2011. Gammaretroviral vectors: biology, technology and application. Viruses 3:677713.[PubMed]
59. Schweizer M, Merten OW. 2010. Large-scale production means for the manufacturing of lentiviral vectors. Curr Gene Ther 10:474486.[PubMed]
60. Parolin C, Palù G,. 2003. Virus-based vectors for gene expression in mammalian cells: retrovirus, p 231250. In Makrides SC (ed), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V, Amsterdam, The Netherlands.
61. Miller AD. 2014. Retroviral vectors: from cancer viruses to therapeutic tools. Hum Gene Ther 25:989994.[PubMed]
62. Cockrell AS, Kafri T. 2007. Gene delivery by lentivirus vectors. Mol Biotechnol 36:184204.[PubMed]
63. Schott JW, Hoffmann D, Schambach A. 2015. Retrovirus-based vectors for transient and permanent cell modification. Curr Opin Pharmacol 24:135146.[PubMed]
64. Yi Y, Noh MJ, Lee KH. 2011. Current advances in retroviral gene therapy. Curr Gene Ther 11:218228.[PubMed]
65. Lévy C, Verhoeyen E, Cosset F-L. 2015. Surface engineering of lentiviral vectors for gene transfer into gene therapy target cells. Curr Opin Pharmacol 24:7985.[PubMed]
66. Pauwels K, Gijsbers R, Toelen J, Schambach A, Willard-Gallo K, Verheust C, Debyser Z, Herman P. 2009. State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr Gene Ther 9:459474.[PubMed]
67. Sanber KS, Knight SB, Stephen SL, Bailey R, Escors D, Minshull J, Santilli G, Thrasher AJ, Collins MK, Takeuchi Y. 2015. Construction of stable packaging cell lines for clinical lentiviral vector production. Sci Rep 5:9021.[PubMed]
68. Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. 1953. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84:570573.[PubMed]
69. Enders JF, Bell JA, Dingle JH, Francis T Jr, Hilleman MR, Huebner RJ, Payne AMM. 1956. Adenoviruses: group name proposed for new respiratory-tract viruses. Science 124:119120.[PubMed]
70. Wold WSM, Ison MG,. 2013. Adenoviruses, p 17321767. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
71. Berk AJ,. 2013. Adenoviridiae, p. 17041731. In Knipe DM, Howley PM (ed.), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
72. Wang I, Huang I. 2000. Adenovirus technology for gene manipulation and functional studies. Drug Discov Today 5:1016.[PubMed]
73. Bourbeau D, Zeng Y, Massie B,. 2003. Virus-based vectors for gene expression in mammalian cells: adenovirus, p 109124. In Makrides SC (ed), Gene Transfer and Expression in Mammalian Cells. Elsevier Science B. V, Amsterdam, The Netherlands
74. McVey D, Zuber M, Brough DE, Kovesdi I. 2003. Adenovirus vector library: an approach to the discovery of gene and protein function. J Gen Virol 84:34173422.[PubMed]
75. Ames RS, Lu Q. 2009. Viral-mediated gene delivery for cell-based assays in drug discovery. Expert Opin Drug Discov 4:243256.[PubMed]
76. Hackett NR, Crystal RG,. 2009. Adenoviruses for gene therapy, p. 3968. In Templeton NS (ed), Gene and Cell Therapy, 3rd ed. CRC Press, Taylor & Francis Group, Boca Raton, FL.
77. Brunetti-Pierri N, Ng P,. 2009. Helper-dependent adenoviral vectors for gene therapy, p. 87114. In Templeton NS (ed), Gene and Cell Therapy, 3rd ed. CRC Press, Taylor & Francis Group, Boca Raton, FL.
78. Toth K, Dhar D, Wold WS. 2010. Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 10:353368.[PubMed]
79. Crystal RG. 2014. Adenovirus: the first effective in vivo gene delivery vector. Hum Gene Ther 25:311.[PubMed]
80. Appaiahgari MB, Vrati S. 2015. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opin Biol Ther 15:337351.[PubMed]
81. Zhang C, Zhou D. 2016. Adenoviral vector-based strategies against infectious disease and cancer. Hum Vaccin Immunother 22:111. ePub.[PubMed]
82. Kovesdi I, Hedley SJ. 2010. Adenoviral producer cells. Viruses 2:16811703.[PubMed]
83. Hitt MM, Parks RJ, Graham FL,. 1999. Structure and genetic organization of adenovirus vectors, p 6186. In Friedmann T (ed), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
84. Wivel NA, Gao GP, Wilson JM,. 1999. Adenovirus vectors, p 87110. In Friedmann T (ed), The Development of Human Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
85. Dion LD, Fang J, Garver RI Jr. 1996. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks. J Virol Methods 56:99107.[PubMed]
86. Ishii-Watabe A, Uchida E, Iwata A, Nagata R, Satoh K, Fan K, Murata M, Mizuguchi H, Kawasaki N, Kawanishi T, Yamaguchi T, Hayakawa T. 2003. Detection of replication-competent adenoviruses spiked into recombinant adenovirus vector products by infectivity PCR. Mol Ther 8:10091016.[PubMed]
87. Wang F, Patel DK, Antonello JM, Washabaugh MW, Kaslow DC, Shiver JW, Chirmule N. 2003. Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens. Hum Gene Ther 14:2536.[PubMed]
88. Lichtenstein DL, Wold WSM. 2004. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther 11:819829.[PubMed]
89. Murakami P, Havenga M, Fawaz F, Vogels R, Marzio G, Pungor E, Files J, Do L, Goudsmit J, McCaman M. 2004. Common structure of rare replication-deficient E1-positive particles in adenoviral vector batches. J Virol 78:62006208.[PubMed]
90. Schalk JA, de Vries CG, Orzechowski TJ, Rots MG. 2007. A rapid and sensitive assay for detection of replication-competent adenoviruses by a combination of microcarrier cell culture and quantitative PCR. J Virol Methods 145:8995.[PubMed]
91. Harui A, Suzuki S, Kochanek S, Mitani K. 1999. Frequency and stability of chromosomal integration of adenovirus vectors. J Virol 73:61416146.[PubMed]
92. Stephen SL, Sivanandam VG, Kochanek S. 2008. Homologous and heterologous recombination between adenovirus vector DNA and chromosomal DNA. J Gene Med 10:11761189.[PubMed]
93. Stephen SL, Montini E, Sivanandam VG, Al-Dhalimy M, Kestler HA, Finegold M, Grompe M, Kochanek S. 2010. Chromosomal integration of adenoviral vector DNA in vivo. J Virol 84:99879994.[PubMed]
94. Oualikene W, Gonin P, Eloit M. 1994. Short and long term dissemination of deletion mutants of adenovirus in permissive (cotton rat) and non-permissive (mouse) species. J Gen Virol 75:27652768.[PubMed]
95. Tiesjema B, Hermsen HP, van Eijkeren JC, Brandon EF. 2010. Effect of administration route on the biodistribution and shedding of replication-deficient HAdV-5: a qualitative modelling approach. Curr Gene Ther 10:107127.
96. Kallel H, Kamen AA. 2015. Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials. Biotechnol J 10:741747.[PubMed]
97. Fox JP, Hall CE, Cooney MK. 1977. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol 105:362386.[PubMed]
98. Trentin JJ, Yabe Y, Taylor G. 1962. The quest for human cancer viruses. Science 137:835841.[PubMed]
99. Green M, Wold WSM, Brackmann KH,. 1980. Human adenovirus transforming genes: group relationships, integration, expression in transformed cells and analysis of human cancers and tonsils, p 373397. In Essex M, Todaro G, zur Hausen H (ed), Cold Spring Harbor Conference on Cell Proliferation and Viruses in Naturally Occurring Tumors. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
100. Bagutti C, Alt M, Schmidlin M, Vogel G, Vögeli U, Brodmann P. 2011. Detection of adeno- and lentiviral (HIV1) contaminations on laboratory surfaces as a tool for the surveillance of biosafety standards. J Appl Microbiol 111:7082.[PubMed]
101. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health. 2009. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication no. (CDC) 21-112. http://www.cdc.gov/biosafety/publications/bmbl5/BMBL.pdf.
102. Knudsen RC,. 1998. Risk assessment for biological agents in the laboratory. In Richmond JY (ed), Rational Basis for Biocontainment: Proceedings of the Fifth National Symposium on Biosafety. American Biological Safety Association, Mundelein, IL.
103. Samulski RJ, Sally M, Muzyczka N,. 1999. Adeno-associated viral vectors, p 131172. In Friedmann T (ed), The Development of Gene Therapy. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
104. Berns KI, Parrish CR,. 2013. Parvoviridiae, p 17681791. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
105. Carter BJ, Burstein H, Peluso RW,. 2009. Adeno-associated virus and AAV vectors for gene delivery, p 115158. In Templeton NS (ed), Gene and Cell Therapy, 3rd ed. CRC Press, Taylor & Francis Group, Boca Raton, FL.
106. Weitzman MD, Linden RM. 2011. Adeno-associated virus biology. Methods Mol Biol 807:123.[PubMed]
107. Kotin RM. 2011. Large-scale recombinant adeno-associated virus production. Hum Mol Genet 20(R1):R2R6.[PubMed]
108. Lisowski L, Tay SS, Alexander IE. 2015. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol 24:5967.[PubMed]
109. Büning H, Huber A, Zhang L, Meumann N, Hacker U. 2015. Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol 24:94104.[PubMed]
110. Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. 2015. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 47:11871193.[PubMed]
111. Russell DW, Grompe M. 2015. Adeno-associated virus finds its disease. Nat Genet 47:11041105.[PubMed]
112. Schultz BR, Chamberlain JS. 2008. Recombinant adeno-associated virus transduction and integration. Mol Ther 16:11891199.[PubMed]
113. Pellet PE, Roizman B,. 2013. Herpesviridiae, p 18021822. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
114. Roizman B, Knipe DM, Whitely RJ,. 2013. Herpes simplex viruses, p 18231897. In Knipe DM, Howley PM (ed), Fields Virology, 6th ed. Lippincott Williams and Wilkins, Philadelphia, PA.
115. Glorioso JC. 2014. Herpes simplex viral vectors: late bloomers with big potential. Hum Gene Ther 25:8391.[PubMed]
116. Parker JN, Bauer DF, Cody JJ, Markert JM. 2009. Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6:558569.[PubMed]
117. Yeomans DC, Wilson SP. 2009. Herpes virus-based recombinant herpes vectors: gene therapy for pain and molecular tool for pain science. Gene Ther 16:502508.[PubMed]
118. Manservigi R, Argnani R, Marconi P. 2010. HSV recombinant vectors for gene therapy. Open Virol J 4:123156.[PubMed]
119. Zemp FJ, Corredor JC, Lun X, Muruve DA, Forsyth PA. 2010. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. Cytokine Growth Factor Rev 21:103117.[PubMed]
120. Ledford H. 2015. Cancer-fighting viruses win approval. Nature 526:622623.[PubMed]
121. Post LE, Roizman B. 1981. A generalized technique for deletion of specific genes in large genomes: a gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25:227232.[PubMed]
122. Parker JN, Zheng X, Luckett W Jr, Markert JM, Cassady KA. 2011. Strategies for the rapid construction of conditionally-replicating HSV-1 vectors expressing foreign genes as anticancer therapeutic agents. Mol Pharm 8:4449.[PubMed]
123. Goins WF, Huang S, Cohen JB, Glorioso JC. 2014. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol 1144:6379.[PubMed]
124. Spaete RR, Frenkel N. 1982. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 30:295304.[PubMed]
125. Oehmig A, Fraefel C, Breakefield XO. 2004. Update on herpesvirus amplicon vectors. Mol Ther 10:630643.[PubMed]
126. Santos K, Duke CMP, Dewhurst S. 2006. Amplicons as vaccine vectors. Curr Gene Ther 6:383392.[PubMed]
127. Lim F, Khalique H, Ventosa M, Baldo A. 2013. Biosafety of gene therapy vectors derived from herpes simplex virus type 1. Curr Gene Ther 13:478491.[PubMed]
128. Condreay JP, Kost TA. 2007. Baculovirus expression vectors for insect and mammalian cells. Curr Drug Targets 8:11261131.[PubMed]
129. Rohrmann GF. 2013. Baculovirus Molecular Biology, 3rd ed. Bookshelf ID: NBK114593. National Center for Biotechnology Information, Bethesda, MD. http://www.ncbi.nlm.nih.gov/books/NBK114593/.
130. Boyce FM, Bucher NL. 1996. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA 93:23482352.[PubMed]
131. Kost TA, Condreay JP, Ames RS. 2010. Baculovirus gene delivery: a flexible assay development tool. Curr Gene Ther 10:168173.[PubMed]
132. Chen C-Y, Wu H-H, Chen C-P, Chern S-R, Hwang S-M, Huang S-F, Lo W-H, Chen G-Y, Hu Y-C. 2011. Biosafety assessment of human mesenchymal stem cells engineered by hybrid baculovirus vectors. Mol Pharm 8:15051514.[PubMed]
133. Hitchman RB, Murguía-Meca F, Locanto E, Danquah J, King LA. 2011. Baculovirus as vectors for human cells and applications in organ transplantation. J Invertebr Pathol 107(Suppl):S49S58.[PubMed]
134. Takata Y, Kishine H, Sone T, Andoh T, Nozaki M, Poderycki M, Chesnut JD, Imamoto F. 2011. Generation of iPS cells using a BacMam multigene expression system. Cell Struct Funct 36:209222.[PubMed]
135. Zhang J, Chen XW, Tong TZ, Ye Y, Liao M, Fan HY. 2014. BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens. Vaccine 32:664670.[PubMed]
136. Keil GM, Pollin R, Müller C, Giesow K, Schirrmeier H. 2016. BacMam platform for vaccine antigen delivery. Methods Mol Biol 1349:105119.[PubMed]
137. Hu YC. 2008. Baculoviral vectors for gene delivery: a review. Curr Gene Ther 8:5465.[PubMed]
138. Kost TA, Condreay JP. 2002. Innovations—biotechnology: Baculovirus vectors as gene transfer vectors for mammalian cells: biosafety considerations. Appl Biosaf 7:167169.
139. O'Reilly DR, Miller LK, Luckow VA. 1994. Baculovirus Expression Vectors: A Laboratory Manual. Oxford University Press, New York, NY.
140. Kaikkonen MU, Ylä-Herttuala S, Airenne KJ. 2011. How to avoid complement attack in baculovirus-mediated gene delivery. J Invertebr Pathol 107(Suppl):S71S79.[PubMed]
141. Tani H, Limn CK, Yap CC, Onishi M, Nozaki M, Nishimune Y, Okahashi N, Kitagawa Y, Watanabe R, Mochizuki R, Moriishi K, Matsuura Y. 2003. In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol 77:97999808.[PubMed]
142. Donello JE, Loeb JE, Hope TJ. 1998. Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J Virol 72:50855092.[PubMed]
143. Russell SJ, Peng KW. 2009. Measles virus for cancer therapy. Curr Top Microbiol Immunol 330:213241.[PubMed]
144. Ehrengruber MU, Schlesinger S, Lundstrom K. 2011. Alphaviruses: semliki forest virus and sindbis virus vectors for gene transfer into neurons. Curr Prot Neurosci 57:4.22.14.22.27.
145. Kim DS, Nam JH. 2011. Application of attenuated coxsackievirus B3 as a viral vector system for vaccines and gene therapy. Hum Vaccin 7:410416.[PubMed]
146. Louboutin JP, Marusich E, Fisher-Perkins J, Dufour JP, Bunnell BA, Strayer DS. 2011. Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe. Gene Ther 18:682691.[PubMed]
147. Reynard O, Mokhonov V, Mokhonova E, Leung J, Page A, Mateo M, Pyankova O, Georges-Courbot MC, Raoul H, Khromykh AA, Volchkov VE. 2011. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 204(Suppl 3):S1060S1065.[PubMed]
148. Lindemann D, Rethwilm A. 2011. Foamy virus biology and its application for vector development. Viruses 3:561585.[PubMed]
149. Ayala-Breton C, Barber GN, Russell SJ, Peng KW. 2012. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 23:484491.[PubMed]
150. Tani H, Morikawa S, Matsuura Y. 2012. Development and applications of VSV vectors based on cell tropism. Front Microbiol 2:272.[PubMed]
151. Gomme EA, Wanjalla CN, Wirblich C, Schnell MJ. 2011. Rabies virus as a research tool and viral vaccine vector. Adv Virus Res 79:139164.[PubMed]
152. Ramsey JD, Vu HN, Pack DW. 2010. A top-down approach for construction of hybrid polymer-virus gene delivery vectors. J Control Release 144:3945.[PubMed]
153. Jurgens CK, Young KR, Madden VJ, Johnson PR, Johnston RE. 2012. A novel self-replicating chimeric lentivirus-like particle. J Virol 86:246261.[PubMed]
154. Jang JH, Schaffer DV, Shea LD. 2011. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther 19:14071415.[PubMed]
155. Zamarin D, Palese P. 2012. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 7:347367.[PubMed]
156. Fueyo J, Gomez-Manzano C, Alemany R, Lee PSY, McDonnell TJ, Mitlianga P, Shi Y-X, Levin VA, Yung WKA, Kyritsis AP. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:212.[PubMed]
157. Goetz C, Dobrikova E, Shveygert M, Dobrikov M, Gromeier M. 2011. Oncolytic poliovirus against malignant glioma. Future Virol 6:10451058.[PubMed]
158. Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, Guo ZS. 2013. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103.[PubMed]
159. Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, Kondziolka D, Krisky D, Goss J, Deluca N, Murphey-Corb M, Glorioso JC. 2004. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther 11:16751684.[PubMed]
160. Sastry L, Cornetta K. 2009. Detection of replication competent retrovirus and lentivirus. Methods Mol Biol 506:243263.[PubMed]
161. Cornetta K, Yao J, Jasti A, Koop S, Douglas M, Hsu D, Couture LA, Hawkins T, Duffy L. 2011. Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther 19:557566.[PubMed]
162. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LCM. 2007. An inventory of shedding data from clinical gene therapy trials. J Gene Med 9:910921.[PubMed]
163. Gonin P, Gaillard C. 2004. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther 11(Suppl 1):S98S108.[PubMed]
164. Wilson CA, Cichutek K. 2009. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Methods Mol Biol 506:477488.[PubMed]
165. Qasim W, Gaspar HB, Thrasher AJ. 2009. Progress and prospects: gene therapy for inherited immunodeficiencies. Gene Ther 16:12851291.[PubMed]
166. Aiuti A, Roncarolo MG. 2009. Ten years of gene therapy for primary immune deficiencies. Hematology (Am Soc Hematol Educ Program) 2009:682689.[PubMed]
167. Gene Therapy Expert Group of the Committee for Proprietary Medicinal Products (CPMP), European Agency for the Evaluation of Medicinal Products–June 2003 Meeting. 2004. Insertional mutagenesis and oncogenesis: update from non-clinical and clinical studies. J Gene Med 6:127129.
168. Ginn SL, Liao SH, Dane AP, Hu M, Hyman J, Finnie JW, Zheng M, Cavazzana-Calvo M, Alexander SI, Thrasher AJ, Alexander IE. 2010. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression. Mol Ther 18:965976.[PubMed]
169. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM. 2006. Gene therapy: therapeutic gene causing lymphoma. Nature 440:1123.[PubMed]
170. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, Cavallesco R, Gillet-Legrand B, Caccavelli L, Sgarra R, Maouche-Chrétien L, Bernaudin F, Girot R, Dorazio R, Mulder GJ, Polack A, Bank A, Soulier J, Larghero J, Kabbara N, Dalle B, Gourmel B, Socie G, Chrétien S, Cartier N, Aubourg P, Fischer A, Cornetta K, Galacteros F, Beuzard Y, Gluckman E, Bushman F, Hacein-Bey-Abina S, Leboulch P. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467:318322.[PubMed]
171. Mátrai J, Chuah MK, VandenDriessche T. 2010. Recent advances in lentiviral vector development and applications. Mol Ther 18:477490.[PubMed]
172. Zhou S, Mody D, DeRavin SS, Hauer J, Lu T, Ma Z, Hacein-Bey Abina S, Gray JT, Greene MR, Cavazzana-Calvo M, Malech HL, Sorrentino BP. 2010. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood 116:900908.[PubMed]
173. Ciuffi A. 2008. Mechanisms governing lentivirus integration site selection. Curr Gene Ther 8:419429.[PubMed]
174. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, Cesani M, Benedicenti F, Plati T, Rubagotti E, Merella S, Capotondo A, Sgualdino J, Zanetti G, von Kalle C, Schmidt M, Naldini L, Montini E. 2011. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117:53325339.[PubMed]
175. National Institutes of Health Recombinant DNA Advisory Committee. 2006. Biosafety considerations for research with lentiviral vectors. http://osp.od.nih.gov/office-biotechnology-activities/biosafety-guidance-institutional-biosafety-committees/guidance-biosafety-considerations-research-lentiviral-vectors-0.
176. Wickersham IR, Finke S, Conzelmann KK, Callaway EM. 2007. Retrograde neuronal tracing with a deletion-mutant rabies virus. Nat Methods 4:4749.[PubMed]
177. Wickersham IR, Sullivan HA, Seung HS. 2010. Production of glycoprotein-deleted rabies viruses for monosynaptic tracing and high-level gene expression in neurons. Nat Protoc 5:595606.[PubMed]
178. Tufaro F. 1997. Virus entry: two receptors are better than one. Trends Microbiol 5:257258, discussion 258–259.[PubMed]
179. Johann SV, Gibbons JJ, O'Hara B. 1992. GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol 66:16351640.[PubMed]
180. Almåsbak H, Aarvak T, Vemuri MC. 2016. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res 2016:5474602.[PubMed]
181. Kuo CY, Kohn DB. 2016. Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep 16:39.[PubMed]
182. Journal of Gene Medicine. 2015. Gene therapy clinical trials worldwide. John Wiley and Sons Ltd., Hoboken, NJ. http://www.abedia.com/wiley/index.html.

Tables

Generic image for table
Table 1.

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Generic image for table
Table 2.

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10
Generic image for table
Table 3.

Citation: Condreay J, Kost T, Mickelson C. 2017. Emerging Considerations in Virus-Based Gene Transfer Systems, p 221-246. In Wooley D, Byers K (ed), Biological Safety: Principles and Practices, Fifth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555819637.ch10

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error